Breast cancer research and treatment · 2026
Interstitial lung disease in metastatic breast cancer: a landscape review using SEER-Medicare.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Pinheiro Laura C, An Anjile, Landry Chrystal A, Tonorezos Emily, Aronson Kerri I
Аннотация
INTRODUCTION: Interstitial lung disease (ILD) is a serious side effect of certain mBC treatments, but our understanding of its prevalence outside of clinical trials and treatment-specific studies is limited. We sought to characterize the incidence of ILD among a large, population-based cohort of adults with mBC in the United States.
METHODS: We included females and males aged 66 + years who were diagnosed with Stage IV breast cancer (as their first cancer) between January 1, 2002-December 31, 2017, using the SEER-Medicare linked. Our primary outcome was an incident ILD diagnosis after their mBC diagnosis, which was operationalized as a binary outcome. We examined demographic and clinical factors associated with incident ILD using logistic regression models.
RESULTS: Among the 14,343 patients with mBC and no evidence of ILD at baseline, the median age at diagnosis was 76 (IQR 70, 82) years and 98% were female. Overall, 1,806 (12.6%) had an ILD diagnosis after mBC diagnosis. There was no significant difference in proportion of patients who received a pharmacologic treatment that carries the potential risk of ILD between patients who received an ILD diagnosis and those who did not (14% vs. 12%).
CONCLUSIONS: ILD is prevalent in 12.6% of adults with mBC, yet oncology guidelines for monitoring for this intrusive and potentially fatal complication are sparse and non-specific. Patient education raising awareness of ILD symptoms and engaging primary care and pulmonary medicine in may improve patient outcomes and quality of life.
METHODS: We included females and males aged 66 + years who were diagnosed with Stage IV breast cancer (as their first cancer) between January 1, 2002-December 31, 2017, using the SEER-Medicare linked. Our primary outcome was an incident ILD diagnosis after their mBC diagnosis, which was operationalized as a binary outcome. We examined demographic and clinical factors associated with incident ILD using logistic regression models.
RESULTS: Among the 14,343 patients with mBC and no evidence of ILD at baseline, the median age at diagnosis was 76 (IQR 70, 82) years and 98% were female. Overall, 1,806 (12.6%) had an ILD diagnosis after mBC diagnosis. There was no significant difference in proportion of patients who received a pharmacologic treatment that carries the potential risk of ILD between patients who received an ILD diagnosis and those who did not (14% vs. 12%).
CONCLUSIONS: ILD is prevalent in 12.6% of adults with mBC, yet oncology guidelines for monitoring for this intrusive and potentially fatal complication are sparse and non-specific. Patient education raising awareness of ILD symptoms and engaging primary care and pulmonary medicine in may improve patient outcomes and quality of life.